Compare VAC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAC | ARDX |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | VAC | ARDX |
|---|---|---|
| Price | $55.13 | $7.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $63.38 | $12.95 |
| AVG Volume (30 Days) | 532.9K | ★ 4.2M |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.58 | N/A |
| Revenue | ★ $3,358,000,000.00 | $398,234,000.00 |
| Revenue This Year | $54.00 | $22.44 |
| Revenue Next Year | $2.00 | $34.00 |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | 5.13 | ★ 58.12 |
| 52 Week Low | $44.58 | $3.21 |
| 52 Week High | $91.18 | $8.40 |
| Indicator | VAC | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 53.15 |
| Support Level | $54.35 | $6.92 |
| Resistance Level | $56.42 | $7.43 |
| Average True Range (ATR) | 2.00 | 0.35 |
| MACD | -0.08 | -0.11 |
| Stochastic Oscillator | 39.93 | 30.07 |
Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.